BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pulmonary Arterial Hypertension readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Pulmonary Arterial Hy
 pertension\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03683186-524@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ralinepag: Phase 3 readout est. (NCT03683186)
DESCRIPTION:Ralinepag\, phase 3\, Pulmonary Arterial Hypertension.\nStudy: 
 A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subje
 cts With PAH Via an Open-Label Extension\nEstimated primary completion: De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ralinepa
 g#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 683186
URL:https://assetmemo.bio/drug/ralinepag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06274801-535@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Seralutinib: Phase 3 readout est. (NCT06274801)
DESCRIPTION:Seralutinib\, phase 3\, Pulmonary Arterial Hypertension.\nStudy
 : Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PR
 OSERA-EXT)\nEstimated primary completion: December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/seralutinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06274801
URL:https://assetmemo.bio/drug/seralutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175038-545@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:ROC-101: Phase 2 readout est. (NCT07175038)
DESCRIPTION:ROC-101\, phase 2\, Pulmonary Arterial Hypertension.\nStudy: A 
 Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) an
 d Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH
 ) (ROCSTAR STUDY)\nEstimated primary completion: March 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/roc-101#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07175038
URL:https://assetmemo.bio/drug/roc-101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846554-540@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:APL-9796: Phase 2 readout est. (NCT06846554)
DESCRIPTION:APL-9796\, phase 2\, Pulmonary Arterial Hypertension.\nStudy: A
  Trial of "APL-9796'' in Adults With Pulmonary Hypertension\nEstimated pri
 mary completion: 30 August 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/apl-9796#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06846554
URL:https://assetmemo.bio/drug/apl-9796#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177703-520@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Treprostinil (Tyvaso): Phase 2 readout est. (NCT07177703)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 2\, Pulmonary Arterial Hypertensi
 on.\nStudy: Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmo
 nary Arterial Hypertension\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/treprostinil-tyvaso
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071
 77703
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357974-534@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Winrevair (Sotatercept): Phase 1/2 readout est. (NCT07357974)
DESCRIPTION:Winrevair (Sotatercept)\, phase 1/2\, Pulmonary Arterial Hypert
 ension.\nStudy: Impact of Sotatercept on Pulmonary Artery and Right Ventri
 cle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH
 \nEstimated primary completion: 1 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sotatercept#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07357974
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318597-547@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280227
DTEND;VALUE=DATE:20280228
SUMMARY:Vasigrobart: Phase 2 readout est. (NCT07318597)
DESCRIPTION:Vasigrobart\, phase 2\, Pulmonary Arterial Hypertension.\nStudy
 : Study of REGN13335 in Adult Participants With Pulmonary Arterial Hyperte
 nsion (PAH)\nEstimated primary completion: 27 February 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vasigrobart#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07318597
URL:https://assetmemo.bio/drug/vasigrobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07143448-234@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:HS235: Phase 1/2 readout est. (NCT07143448)
DESCRIPTION:HS235\, phase 1/2\, Pulmonary Arterial Hypertension.\nStudy: A 
 Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in A
 dults\nEstimated primary completion: March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/hs235#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07143448
URL:https://assetmemo.bio/drug/hs235#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498803-534@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT07498803)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2\, Pulmonary Arterial Hyperten
 sion.\nStudy: Sota-ES - Sotatercept in Patients With Congenital Heart Dise
 ase and Eisenmenger´s Syndrome\nEstimated primary completion: 31 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/sotatercept#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07498803
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824674-517@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Revatio (sildenafil): Phase 2/3 readout est. (NCT07824674)
DESCRIPTION:Revatio (sildenafil)\, phase 2/3\, Pulmonary Arterial Hypertens
 ion.\nStudy: The Effect of Additive On-Demand Sildenafil vs. Dextrose Cand
 y on Maximum Exercise Capacity in Pulmonary Arterial Hypertension\nEstimat
 ed primary completion: April 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sildenafil#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07824674
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612657-549@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Extended-release tacrolimus (VI-0106): Phase 3 readout est. (NCT076
 12657)
DESCRIPTION:Extended-release tacrolimus (VI-0106)\, phase 3\, Pulmonary Art
 erial Hypertension.\nStudy: A Phase 3 Study of Extended-release Tacrolimus
  in Subjects With Pulmonary Arterial Hypertension and Functional Limitatio
 ns\nEstimated primary completion: 31 May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/extended-release-tacrolimus-vi-0106#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07612657
URL:https://assetmemo.bio/drug/extended-release-tacrolimus-vi-0106#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925750-534@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280616
DTEND;VALUE=DATE:20280617
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT06925750)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2\, Pulmonary Arterial Hyperten
 sion.\nStudy: A Clinical Study of Sotatercept (MK-7962) in People With Pul
 monary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)\nEstimated p
 rimary completion: 16 June 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sotatercept#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06925750
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05587712-534@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280921
DTEND;VALUE=DATE:20280922
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT05587712)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2\, Pulmonary Arterial Hyperten
 sion.\nStudy: Study to Evaluate Sotatercept (MK-7962) in Children With Pul
 monary Arterial Hypertension (PAH) (MK-7962-008)\nEstimated primary comple
 tion: 21 September 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sotatercept#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05587712
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266519-534@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT07266519)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2\, Pulmonary Arterial Hyperten
 sion.\nStudy: SIRIUS - Initial Combination Therapy With an Endothelin Rece
 ptor Antagonist\, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patie
 nts With Newly Diagnosed Pulmonary Arterial Hypertension\nEstimated primar
 y completion: October 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/sotatercept#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07266519
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06350032-11040@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Treprostinil (Remodulin): Phase 3 readout est. (NCT06350032)
DESCRIPTION:Treprostinil (Remodulin)\, phase 3\, Pulmonary Arterial Hyperte
 nsion.\nStudy: Investigational Trial to Evaluate Safety and Tolerability o
 f Treprostinil in Children Diagnosed With PAH\nEstimated primary completio
 n: November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tre
 prostinil-remodulin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06350032
URL:https://assetmemo.bio/drug/treprostinil-remodulin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218029-534@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20281207
DTEND;VALUE=DATE:20281208
SUMMARY:Winrevair (Sotatercept): Phase 3 readout est. (NCT07218029)
DESCRIPTION:Winrevair (Sotatercept)\, phase 3\, Pulmonary Arterial Hyperten
 sion.\nStudy: A Clinical Study of Sotatercept (MK-7962) in People With Pul
 monary Arterial Hypertension (MK-7962-038)\nEstimated primary completion: 
 7 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sota
 tercept#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07218029
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06351345-534@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290204
DTEND;VALUE=DATE:20290205
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT06351345)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2\, Pulmonary Arterial Hyperten
 sion.\nStudy: 129 Xenon Imaging in Patients Treated With Sotatercept\nEsti
 mated primary completion: 4 February 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sotatercept#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06351345
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245680-513@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290214
DTEND;VALUE=DATE:20290215
SUMMARY:Letairis (Ambrisentan): Phase 3 readout est. (NCT07245680)
DESCRIPTION:Letairis (Ambrisentan)\, phase 3\, Pulmonary Arterial Hypertens
 ion.\nStudy: COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy i
 n PAH With Cardiovascular Comorbidities\nEstimated primary completion: 14 
 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ambris
 entan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07245680
URL:https://assetmemo.bio/drug/ambrisentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646860-534@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290524
DTEND;VALUE=DATE:20290525
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT07646860)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2\, Pulmonary Arterial Hyperten
 sion.\nStudy: A Study of Sotatercept (MK-7962) in Japanese Children With P
 ulmonary Arterial Hypertension (PAH) (MK-7962-032)\nEstimated primary comp
 letion: 24 May 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sotatercept#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07646860
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365332-538@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Imatinib mesylate prodrug (IkT-001Pro): Phase 3 readout est. (NCT07
 365332)
DESCRIPTION:Imatinib mesylate prodrug (IkT-001Pro)\, phase 3\, Pulmonary Ar
 terial Hypertension.\nStudy: An Adaptive Program of IKT-001 in Pulmonary A
 rterial Hypertension (PAH)\nEstimated primary completion: June 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/imatinib-mesylate-prodrug-
 ikt-001pro#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07365332
URL:https://assetmemo.bio/drug/imatinib-mesylate-prodrug-ikt-001pro#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07632898-538@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Imatinib mesylate prodrug (IkT-001Pro): Phase 3 readout est. (NCT07
 632898)
DESCRIPTION:Imatinib mesylate prodrug (IkT-001Pro)\, phase 3\, Pulmonary Ar
 terial Hypertension.\nStudy: Open-Label Study of IKT-001 in Pulmonary Arte
 rial Hypertension (PAH)\nEstimated primary completion: 30 June 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/imatinib-mesylate-prodrug-
 ikt-001pro#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07632898
URL:https://assetmemo.bio/drug/imatinib-mesylate-prodrug-ikt-001pro#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
